Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
A$ 3.29
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Strong growth
Data is available to registered users only
Data is available to registered users only
About
Artrya Limited operates as a medical technology company that uses artificial intelligence (AI) to identify patients at risk of coronary artery disease. It offers Salix, a cloud-based software that uses its AI to automate the detection of coronary artery disease from coronary computed tomography angiography. The company was incorporated in 2018 and is based in West Perth, Australia.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Data is available to registered users only
Target Price
The average target price of AYA.AX is 3.1 and suggests 6% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to dec
Data is available to registered users only
Buy
Sell